IE
DCOY

Israel Englander’s Decoy Therapeutics DCOY Stock Holding History

Israel Englander’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed -$23K – 7013
2022
Q3 		$23K Sell
3
-5
-63% -$37.8K ﹤0.01% 6430
2022
Q2 		$61K Buy
8
+7
+700% +$60.4K ﹤0.01% 6125
2022
Q1 		$8K Sell
1
-1
-50% -$15.8K ﹤0.01% 6751
2021
Q4 		$32K Hold
2
– – ﹤0.01% 6557
2021
Q3 		$61K Buy
2
+1
+100% +$34.5K ﹤0.01% 6545
2021
Q2 		$35K Hold
1
– – ﹤0.01% 6398
2021
Q1 		$42K Hold
1
– – ﹤0.01% 5785
2020
Q4 		$19K Hold
1
– – ﹤0.01% 5132
2020
Q3 		$23 Buy
+1
New +$39.6K ﹤0.01% 4341
2018
Q2 		– Hold
0
– -$301K – 4140
2018
Q1 		– Hold
0
– – – 3215
2017
Q4 		– Hold
0
– – – 3635
2017
Q3 		– Hold
0
– – – 3140
2017
Q2 		– Hold
0
– – – 2769
2017
Q1 		– Hold
0
– – – 2891
2016
Q4 		– Hold
0
– – – 2407

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Israel Englander's DCOY Position: Q4 2022 in Review

Israel Englander sold out of Decoy Therapeutics (DCOY) in Q4 2022, closing a stake of 3 shares — an estimated $23K sold.

Israel Englander first reported a position in DCOY in Q3 2020 and held it in 9 quarters. The position peaked at $61K in Q2 2022. 4 funds tracked by Wall St. Rank hold DCOY as of Q4 2022.

  • Israel Englander reported no remaining Decoy Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Israel Englander sold 3 Decoy Therapeutics shares in Q4 2022, an estimated $23K.
  • Israel Englander first reported a position in Decoy Therapeutics in Q3 2020 and held it in 9 quarters.
  • Israel Englander's Decoy Therapeutics position peaked at $61K in Q2 2022.
  • 4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.